FDA: If Outsource Compounders Don't Pay Fee, Drugs Will Be 'Misbranded' (Daily News - 04-04-2014)

FDA says drugs compounded by outsourcing facilities that do not pay the newly created fees will be deemed misbranded and in recently released guidance lays out the process to resolve disputes involving issues such as small business fee reduction denials.
quoted from InsideHealthReform.com